Belgium's Solvay has announced plans to buy back and expand a productionunit in the Netherlands where the company's Influvac influenza vaccine is currently bulk manufactured by American Home Products. Financial terms of the deal were not disclosed, but it was noted that the firm is making the purchase three years before a buyback option is due to expire.
Solvay said that the decision to expand the plant in Weesp is due to the fast-growing demand for Influvac, adding that it will also increase the filling capacity of its site in Olst, the Netherlands, where the vaccine is filled into syringes. Sales of Influvac have tripled since 1995, the company said, noting that they reached 50 million euros ($44.1 million) in 2000, and predicted further growth for the vaccine.
Further flu developments
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze